Skip to main content
Clinical Trials/CTRI/2024/02/062867
CTRI/2024/02/062867
Not yet recruiting
Phase 4

A prospective randomized study to evaluate the effects of intrathecal magnesiumsulphate as an adjuvant to Bupivacaine hydrochloride in spinal anaesthesia. - NI

Anupama Kumari0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: K40-K46- HerniaHealth Condition 2: M15-M19- OsteoarthritisHealth Condition 3: N20-N23- Urolithiasis
Sponsor
Anupama Kumari
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Anupama Kumari

Eligibility Criteria

Inclusion Criteria

  • 1\.Adult patients ranging from 18\-65 years of age
  • 2\.Patients undergoing infra\-umbilical surgeries
  • 3\.Patients belonging to ASA grade 1 and 2

Exclusion Criteria

  • 1\.Patients refusal, uncooperative patients or children
  • 2\.Patients with hepatic, renal, cardiac or respiratory problems.
  • 3\.Patients with localised site infections
  • 4\.Haematological, bleeding disorders and coagulopathies.
  • 5\.Known allergy to magnesium sulphate or other study drugs.

Outcomes

Primary Outcomes

Not specified

Similar Trials